**Megakaryocyte maturation involves activation of the IRE1α-dependent adaptive unfolded**
**protein response**

[1]Faiz, M., [2]Kalev-Zylinska, M.L, [3]Singleton, D.C, [3]Hay, M.P. and [1*]Ledgerwood, E.C.

[1]Department of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin,
New Zealand

[2]Blood and Cancer Biology Laboratory, Department of Molecular Medicine & Pathology,
Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.

[3]Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The
University of Auckland, Auckland, New Zealand

*Corresponding author: liz.ledgerwood@otago.ac.nz

ORCID IDs
MF: 0000-0001-8681-6286
MLK-Z: 0000-0001-8378-8048
DCS: 0000-0002-2044-8078
MPH: 0000-0002-7087-9087
ECL: 0000-0002-4956-6043

**Abstract**

Endoplasmic reticulum stress triggers the unfolded protein response (UPR) to promote cell
survival or apoptosis. Transient endoplasmic reticulum stress activation has been reported to
trigger megakaryocyte production, and UPR activation has been reported as a feature of
megakaryocytic cancers. However, the role of UPR signaling in megakaryocyte biology is not
fully understood. We studied the involvement of UPR in human megakaryocytic differentiation
using PMA (phorbol 12-myristate 13-acetate)-induced maturation of megakaryoblastic cell lines
and thrombopoietin-induced differentiation of human peripheral blood-derived hematopoietic
stem cells. Our results demonstrate that an adaptive UPR mediated by IRE1α (inositol-requiring
enzyme 1α) endonuclease activity is required for megakaryocyte differentiation. Differentiation
did not alter the response to the canonical endoplasmic reticulum stressors DTT or thapsigargin.
However, thapsigargin, but not DTT, inhibited differentiation, consistent with the involvement of
$Ca^{2+}$ signaling in megakaryocyte differentiation.

**Keywords**: megakaryopoiesis, endoplasmic reticulum (ER) stress, unfolded protein response (UPR), calcium, IRE1α, XBP-1

## Introduction

The endoplasmic reticulum (ER) is a vital cellular organelle involved in folding and post-translational modification of secreted and transmembrane proteins, storage of calcium, and metabolism of carbohydrates, with disruptions of these processes leading to ER stress [1-4]. In response to ER stress, eukaryotic cells trigger a tightly coordinated intracellular signaling cascade known as the unfolded protein response (UPR) to maintain protein homeostasis. There are three key UPR signal activators: IRE1α (inositol-requiring enzyme one alpha), PERK (protein kinase R-like ER kinase), and ATF6 (activating transcription factor 6). Once these UPR signal molecules are activated, the continued accumulation of unfolded proteins is prevented by upregulating the expression of chaperones to promote folding, repressing mRNA translation to temporarily inhibit global protein synthesis, and initiating ER-associated degradation (ERAD) pathways. However, if the UPR is unable to restore protein homeostasis, UPR signaling events may cause apoptosis [5, 6].

Previous studies have demonstrated that ER stress and the UPR signaling events are involved in the differentiation of many cell types, including fibroblasts [7], osteoblasts [8], neutrophils [9], plasma cells [10] and mammary epithelial cells [11]. It has been proposed that ER stress activation triggers an apoptotic-like phase of megakaryocyte differentiation in human megakaryoblastic cell lines, and may drive proplatelet formation [12, 13]. Recent studies report that UPR-specific gene expression is upregulated in calreticulin (*CALR*)-mutated megakaryocyte progenitors, increasing survival of the progenitors to contribute to the abnormal accumulation of bone marrow megakaryocytes in myeloproliferative neoplasms [14-18]. Despite these studies showing evidence of UPR activation during normal and abnormal megakaryopoiesis, the precise role of UPR in megakaryocyte biology is not understood.

In this study, we investigated the involvement of UPR signaling and examined the consequences of UPR inhibitors and activators during in vitro maturation of megakaryocytic cell lines and human peripheral blood (PB) derived hematopoietic stem cells (HSC).

## Materials and Methods

*Cell culture and differentiation*

Human megakaryoblastic leukemic cells, MEG-01 (ATCC CRL-2021) [19] and K-562 (ATCC CRL-243) [20], were maintained in RPMI-1640 (Gibco; 3180002) medium supplemented with

10% fetal bovine serum (FBS), sodium bicarbonate (2 g/L), penicillin (100 U/mL), and

streptomycin (100 µg/mL) at 37°C in a 5% $CO_2$ humidified atmosphere. The identity of the cell

lines was confirmed by STR analysis (DNA Diagnostics, NZ) and the cells were confirmed to be

mycoplasma free. In vitro megakaryocytic maturation was induced by treating K-562 or MEG-

01 cells (2.5 x $10^5$ cells/mL) in a 6-well plate with 0.5 nM phorbol-12-myristate-13-acetate

(PMA) (Sigma-Aldrich).

CD45[+] cells were isolated and purified from PB mononuclear cells from individual donors as

previously described [21, 22]. Isolated CD45[+] cells (1 x $10^5$ cells/ml) were cultured in

StemSpan[TM] medium (StemCell Technologies, Vancouver, Canada) supplemented with 10 ng/ml

thrombopoietin (TPO), interleukin (IL) 6 and IL 11 (StemCell Technologies) at 37°C in a

humidified 5% $CO_2$ incubator for 14 days with media changes on days 5, 8, and 11.

*ER stress modulators*

The conventional ER stressors thapsigargin (Tg) (T9033; Sigma-Aldrich) or dithiothreitol (DTT)

(D0632; Sigma-Aldrich), were used to induce ER stress at the indicated concentrations and time

points. The following compounds were used as UPR inhibitors: PF429242-dihydrochloride

(SML0667; Sigma-Aldrich), an ATF6 inhibitor [23], AMG-PERK-44 (HY-12661A,

MedChemExpress), a PERK inhibitor [24], and SN34221 (Supplementary data), an IRE-1α

endonuclease inhibitor [25]. The chemicals were dissolved in DMSO or distilled water, and

DMSO used as a control when appropriate.

*Analysis of megakaryocytic maturation by flow cytometry*

Cells were harvested, washed with Dulbecco's PBS, resuspended in 100 µL of Dulbecco's PBS,

and stained for 30 min in the dark at room temperature. Antibodies used were anti-CD61

phycoerythrin (PE) (1:20; 1075384; BD Biosciences), mouse IgG1 PE (isotype control;

7223589; BD Biosciences), anti-CD41a V450 (1:20; 1011309; BD Biosciences), V450 IgG1

(isotype control; 7128864; BD Biosciences). Live cells were determined with Zombie NIR

(1:100; B312060; BioLegend) or Zombie Green (1:100; B334686; BioLegend). After incubation,

the cells were washed with Dulbecco's PBS or wash buffer (1X Dulbecco's PBS, 1 mM EDTA,

3% FBS), resuspended in FACS buffer (0.01% sodium azide, 0.1% BSA in Dulbecco's PBS)

analyzed using the Guava® easyCyte 5 HPL benchtop flow cytometer (MerckMillipore) or BD

LSRFortessa[TM] cell analyzer (BD Biosciences). Data analysis was performed using FlowJo

version 10 (FlowJo, Ashland, USA). Data reported are geometric mean fluorescence intensity

(MFI) of the live cell (Zombie negative) population.

*RNA isolation and RT-qPCR*

Total RNA was isolated from K-562 and MEG-01 cells using TRIzol (Invitrogen). The

concentration of the RNA was measured using Qubit$^{TM}$ RNA HS Assay Kit (ThermoFisher

Scientific). First-strand cDNA synthesis was performed with 1 µg of total RNA in 20 µL

reaction volume using SuperScript$^{TM}$ IV VILO$^{TM}$ (SSIV VILO) master mix. Real-time

quantitative RT-PCR reactions were run on LightCycler$^{TM}$ 480 Instrument II System (Roche Life

Science) using PowerUp$^{TM}$ SYBER$^{TM}$ Green Master Mix (Thermo Fisher Scientific). All the

procedures were followed as recommended by the manufacturer. The qPCR primer sequences

are shown in Table S1. RT-qPCR was performed in triplicate, and relative expression was

quantified using the Pfaffl method [26]. Data were normalized to hypoxanthine phosphoribosyl

transferase 1 (HPRT) and glyceraldehyde 3-phoshate dehydrogenase (GAPDH) using basket

normalization [27].

*Semi-quantitative PCR analysis for XBP-1 splicing detection*

To detect XBP-1 splicing, XBP-1 mRNA was amplified using XBP-1 primers (forward

5'CCTTGTAGTTGAGAACCAGG 3' and reverse 5' AGGGGCTTGGTATATATGTGG 3'),

and the reactions were carried out in the C1000 Touch$^{TM}$ thermal cycler (Bio-Rad). Briefly, first-

strand cDNA was synthesized with 2 µg of total RNA in 20 µL reaction volume. To amplify

XBP-1 mRNA, 5 µL of undiluted cDNA was used as a template in a 50 µL reaction mixture with

an initial denaturation step for 3 min at 94 °C, followed by 30 cycles of denaturation for 30 s at

94 °C, annealing for 30 s at 54 °C, and extension for 60 s at 72 °C, and a final extension step for

10 min at 72 °C. PCR products were run on 2% (w/v) agarose gel, stained with 0.5 µg/mL

ethidium bromide, and visualized using the Gel Doc$^{TM}$ XR+ Imaging System (Bio-Rad).

*Protein extraction and western blotting*

Cells were lysed in RIPA (radio-immunoprecipitation assay) buffer (50 mM Tris-HCl pH 7.4,

150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate) containing protease and

phosphatase inhibitor cocktail (Sigma-Aldrich; MSSAFE). Total protein (20 µg) was resolved by

SDS PAGE under reducing conditions and transferred to nitrocellulose membrane. Membranes

were stained with REVERT$^{TM}$ 700 total protein stain (LI-COR Biosciences), washed and imaged

on the Odyssey Fc Imaging System (LI-COR Biosciences). The membrane was then blocked

with Intercept® Blocking Buffer (LI-COR Biosciences) for 1 h at room temperature and

incubated overnight with 1:500 anti-GRp78 (BiP) antibody (sc-1050; Santa Cruz) at 4 ℃.

IRDye® 680-LT donkey anti-goat (C60127-06, LI-COR Biosciences) was used as a secondary

antibody, and the blots were visualized in the Odyssey Fc Imaging System. Band intensities were

quantified with Image Studio Lite version 5.2 (LI-COR Biosciences). Briefly, signals from the

total protein stain and target protein were measured, the lane normalization factor (LNF) was

calculated for total protein in each sample, and the target protein band intensities were

normalized using the LNF.

*Statistical analysis*

Statistical analyses were performed using GraphPad Prism software version 8.0 (GraphPad

Software, San Diego, CA, USA). The comparison of means between different groups was

performed using one sample t-test, one-way or two-way ANOVA, or two-tailed Student's t-test.

$P < 0.05$ was considered significant.

**Results**

**The unfolded protein response is activated during megakaryocytic maturation of K-562**
**and MEG-01 cells**

We chose K-562 and MEG-01 cell lines to study the role of UPR activation in megakaryocytic

maturation because both are myeloid cell lines that mature towards megakaryocytes upon PMA

treatment [28, 29]. We confirmed that treatment with 0.5 nM PMA caused an increase in the

expression of the megakaryocytic maturation markers CD61 and *GATA1* over 3 days without

changing cell viability (Figure S1).

To determine whether the UPR is activated during PMA-induced maturation of K-562 and

MEG-01 cells we examined the expression of UPR target genes. The expression of *CHOP*

(*DDIT3*), *ERdj4* (*DNAJB9*), *HERPUD1*, and *XBP1* mRNA was significantly increased in K-562

and MEG-01 cells at day 3 (Figure 1). This suggests that there is activation of the IRE1α and/or

ATF6 arms of the UPR during maturation. PERK/ATF6-dependent *ATF4* and *GADD34*

(*PPP1R15A*) expression was also significantly upregulated in K-562 cells, but not MEG-01 cells,

at day 3 of maturation (Figure S2A,B). *BiP* (*HSPA5*), which is both a UPR sensor and a target,

was not induced in MEG-01 cells, and showed a significant decrease in K-562 cells (Figure 1).

As this was inconsistent with the other UPR targets we also analyzed BiP protein expression and

saw no change upon maturation (Figure S2C). Overall, these results indicate that activation of

UPR signaling pathways occurs during PMA-induced megakaryocytic maturation of K-562 and

MEG-01 cells.

**Figure 1. UPR target gene expression is upregulated during PMA-induced maturation of K-562 and MEG-01 cells into megakaryocytes.** K-562 (A) or MEG-01 (B) cells were treated with 0.5 nM PMA and expression of *CHOP*, *ERdj4*, *HERPUD1*, *XBP1* and *BIP* mRNA at days 0, 1, 2 and 3 was determined by RT-qPCR. Relative expression was calculated using the value at day 0 as 1. N=3 ± SD. *$P < 0.05$, **$P < 0.01$ compared to day 0 (one sample t-test).

**Inhibition of IRE1α endonuclease activity, but not PERK or ATF6, inhibits**

**megakaryocytic maturation**

Having shown that the UPR is activated during megakaryocytic maturation of K-562 and MEG-

01 cells, we next wanted to determine whether activation of one or more arms of the UPR is

required for maturation. To do this we used inhibitors of the IRE1α, PERK and ATF6 UPR

pathways. In the BiP-dependent IRE1α pathway, activation of the IRE1α endonuclease induces

splicing of *XBP1* mRNA [30], with the resulting XBP-1 transcription factor driving gene

expression. We first confirmed that novel IRE1α endonuclease inhibitor SN34221 [25] dose

dependently inhibited DTT-induced *XBP1* splicing in K-562 cells, with complete inhibition at 50

μM (Figure S3). Next the impact of SN34221 on PMA-induced K-562 maturation was

determined. There was an approximate 25% decrease in CD61 MFI in the live cell population

(Figure 2A) and a decrease in *GATA1* expression (Figure 2B) at day 3 with 50 μM SN34221,

with a small decrease in cell viability (Figure S4A). This suggests that activation of the IRE1α

UPR pathway may contribute to K-562 megakaryocytic maturation. Consistent with inhibition of

maturation, SN34221 also decreased the maturation-associated increase in expression of the

XBP-1 target *ERdj4* but not the PERK/ATF6 targets *CHOP*, *ATF4*, *GADD34* or *HERPUD1*

(Figure 2C). In contrast, inhibition of the PERK UPR pathway with AMG-PERK44 [24]

significantly increased CD61 MFI at day 3 in the live cell population (Figure 2D), and inhibited

expression of the PERK targets *CHOP*, *ATF4* and *HERPUD1* (Figure 2E). We also observed a

dose-dependent decrease in cell viability (Figure S4B). Our results with the PERK inhibitor

suggest that the PERK branch of the UPR could have an inhibitory effect on PMA-induced

megakaryocytic maturation but plays a vital role in megakaryocyte survival. Finally, the site-1

protease inhibitor PF-429242 [23] was used to inhibit the ATF6 UPR pathway but no change in

CD61 expression (Figure S4C) or cell viability was observed (Figure S4D) although the

expression of *CHOP*, *ATF4* and *HERPUD1* was significantly decreased (Figure S4E).

**Figure 2. The effect of pharmacological inhibition of UPR on K-562 maturation and HSC differentiation. A and D**. K-562 cells were treated with 0.5 nM PMA in the presence of SN34221 (A) or AMG-PERK44 (C) and expression of CD61determined (fold change MFI compared to day 0). N=3 ± SD *$P < 0.05$, ***$P < 0.001$, ****$P < 0.0001$ (two-way ANOVA). **B and D.** K-562 cells were treated with 0.5 nM PMA in the presence (white bars) or absence (grey bars) of 50 μM SN34221 (B) or 2 μM AMG-PERK44 (D) and relative gene expression measured at day 3. N=3 ± SD. *$P < 0.05$, ** $P<0.01$, ***$P<0.001$ (unpaired t-test). **E.** % CD61+ (light grey bars) or CD61+/CD41+ cells (dark grey bars) at

days 11 and 14 of TPO-induced megakaryocyte differentiation of HSC in the presence of DMSO or 50
μM SN34221. N=3 ± SD *$P < 0.05$ (one-way ANOVA).

Having observed the potential involvement of the IRE1α UPR pathway in megakaryocytic
maturation of K-562 cells, we next wanted to determine whether this pathway was also involved
in TPO-induced differentiation of HSC isolated from human peripheral blood. The IRE1α
endonuclease inhibitor SN34221 significantly decreased the percentage of partially mature
(CD61+) and fully mature (CD61+/CD41+) megakaryocytes at day 14 (Figure 2E). Consistent
with inhibition of differentiation there was no evidence of proplatelet formation or membrane
blebbing at day 14 (Figure S5C). These results indicate that the IRE1α signaling branch of UPR
is involved in megakaryocyte differentiation of HSC.

**214 Activation of ER stress by thapsigargin, but not DTT, inhibits PMA-induced maturation of**
**215 K-562 cells**

Our data suggests that activation of the IRE1α pathway is involved in megakaryocyte
maturation. We next determined whether activation of the IRE1α pathway by an exogenous ER
stress had any impact on megakaryocyte maturation. We confirmed that the ER stressors DTT, a
small-molecule redox reagent for reducing protein disulfide bonds, and thapsigargin, a
sarco/endoplasmic reticulum ATPase (SERCA) inhibitor, induced IRE1α activation as shown by
the splicing of *XBP1* mRNA (Figure S6). Exogenous induction of the UPR by DTT had no
impact on K-562 megakaryocytic maturation (Figure 3A) or viability (Figure 3B). In contrast,
treatment with thapsigargin caused a dose-dependent reduction in PMA-induced maturation of
K-562 cells (Figure 3C) with no change in cell viability (Figure 3D). Thapsigargin also inhibited
TPO-induced HSC differentiation (Figure 3E) and subsequent proplatelet production (Figure
S5D). Overall, these data indicate that while exogenous IRE1α activation does not enhance
megakaryocyte maturation, ER $Ca^{2+}$ homeostasis plays a central role in megakaryocyte
differentiation.

**Figure 3. The effect of UPR activation on K-562 maturation and PBMC differentiation. A - D.** K-562 cells were treated with 0.5 nM PMA for 2 days in the presence of DTT (A and B) or Tg (C and D) and analyzed for expression of CD61 (fold change MFI compared to day 0) (A and C) or cell viability (B and D). N=3 ± SD. *$P < 0.05$, **$P < 0.01$ (one way ANOVA). **E.** % CD61[+] (light grey bars) or CD61[+]/CD41[+] cells (dark grey bars) at days 11 and 14 of TPO-induced megakaryocyte differentiation of HSC in the presence of DMSO or 1 μM Tg. N=3 ± SD *$P < 0.05$ (one-way ANOVA).

**Megakaryocytic maturation of K-562 cells does not alter the response to an exogenous ER stress**

Finally, we examined whether maturation alters the ability of the K-562 or MEG-01 cells to

respond to ER stress. K-562 cells were treated with DTT or thapsigargin before or 3 days after

PMA treatment, and the expression of UPR target genes was quantified by RT-qPCR. DTT

treatment activated the UPR as indicated by a strong induction of *XBP1* splicing, and *CHOP,*

*BIP* and *ATF4* (but not *GADD34*) expression, in immature (untreated) and mature (PMA treated)

K-562 cells (Figure 4A). Similarly, thapsigargin treatment induced *XBP1* splicing and increased

*CHOP, BIP ATF4* and *GADD34* expression in immature K-562 cells, with all but *ATF4* also

showing increased expression in the mature cells (Figure 4B). Similar results were obtained with

MEG-01 cells (Figure S7). These results indicate that even though UPR pathways are activated

during PMA-induced maturation, this does not alter the ability of the cells to further activate

canonical UPR pathways in response to an exogenous ER stressor.

**Figure 4. PMA treated and untreated K-562 cells are similarly responsive to ER stress induced by DTT or thapsigargin.** Immature (no PMA) or mature (PMA) K-562 cells were treated with 10 mM DTT for 0-2 h (A) or 0.1 μM Tg for 0-12 h (B). Expression of *XBP1*s and *XBP1*t, *CHOP*, *BIP*, *ATF4*, and *GADD34* mRNA was quantified by RT-qPCR. Expression is relative to 0 h. N=3 ± SD. *$P < 0.05$, **$P < 0.01$ (one sample t-test).

## Discussion

UPR signaling pathways have been found to play a vital role in organellar development and cellular differentiation in a variety of cell types [7-11, 31, 32]. Furthermore, *CALR* mutations, the second most common driver mutations in classical Philadelphia chromosome-negative MPN myeloproliferative neoplasms [33, 34], are associated with activation of UPR target genes, leading to increased survival and abnormal accumulation of megakaryocyte progenitors in patients' bone marrow [14-18]. However, the role of UPR signaling in normal megakaryocyte differentiation is unclear. Here we have used the K-562 and MEG-01 cell lines and primary HSC to determine how UPR signaling contributes to megakaryocyte differentiation.

UPR signaling can be divided into an adaptive response, allowing a cell to survive in a new environment, and a terminal response, which triggers cell death [5, 6]. The balance between these two responses depends upon the nature of the initial stress, and the success of the adaptive response. Early reports suggested that localized caspase activation is required for megakaryopoiesis [35, 36], and more recently it has been suggested that UPR signaling drives caspase activation via the intrinsic apoptosis pathway during maturation [12, 13]. However, the role of caspase activation in megakaryopoiesis is uncertain, with genetic studies in mice convincingly showing that intrinsic apoptosis must be suppressed for successful differentiation [37, 38]. Studies suggesting a role for ER stress-induced apoptosis in megakaryopoiesis have mostly used PMA-induced maturation of various cell lines. However, the PMA concentrations used to induce maturation and draw conclusions about the role of UPR signaling also resulted in extensive cell death [12, 13]. Therefore, it is unclear whether UPR activation in these studies was a specific feature of megakaryocyte maturation or a generalized response to cell stress. In the current study we used a low concentration of PMA that induced megakaryocytic maturation of K-562 and MEG-01 cell lines in the absence of cell death, clearly demonstrating that induction of apoptosis is not required for PMA-induced megakaryocytic maturation. Under these conditions maturation was accompanied by increased transcription of several UPR target genes:

*CHOP*, *XBP1*, *ERDj4*, *HERPUD1*, *ATF4* and *GADD34*. Expression of these genes in the

absence of cell death is consistent with activation of the adaptive UPR. The terminal stages of

megakaryopoiesis involve endomitosis and polyploidization with an accompanying high demand

for synthesis of proteins and membranes prior to proplatelet formation and platelet release [39].

Therefore, it is unsurprising that the adaptive UPR is activated in maturing megakaryocytes. This

would then assist terminal megakaryopoiesis by increasing the biosynthesis of chaperone

proteins, increasing membrane synthesis, and boosting the protein folding capacity of the ER.

Indeed XBP-1 is an important regulator of specialist secretory cells which require a high level of

protein synthesis [32, 40].

To determine which arm of the adaptive UPR was activated, we inhibited IRE1α endonuclease

activity (SN34221), PERK autophosphorylation (AMG-PERK44) and ATF6 cleavage (PF-

429242). SN34221 inhibited PMA-induced maturation of K-562 cells and TPO-induced

differentiation of HSC, implicating the IRE1α pathway in the adaptive UPR. IRE1α is an

endonuclease located in the ER membrane. There are two outcomes of IRE1α endonuclease

activity, *XBP1* splicing to induce expression of proteins involved in ER protein translocation,

folding and secretion, and regulated IRE1-dependent decay (RIDD) [6, 30, 41-44]. Both *XBP1*

splicing and RIDD have been implicated in differentiation of a range of cell types as well as in

*C. elegans* and *Drosophila* development [32, 45-52]. The specific role of *XBP1* splicing in the

hematopoietic compartment has been investigated using a Vav-1 promoter-driven *XBP1*

knockout mouse model, finding a specific defect in eosinophil differentiation, but the number of

bone marrow megakaryocytes and circulating platelets was not determined [53]. Our observation

that both immature and mature K-562 cells show similar responses to DTT and thapsigargin, and

that DTT has no impact on maturation, further suggests that the IRE1α-mediated adaptive

response is distinct from the canonical ER stress response to accumulation of unfolded proteins.

Understanding the specific role of *XBP1* splicing and/or RIDD in megakaryopoiesis requires

further investigation.

Treatment with thapsigargin inhibited both PMA-induced maturation of K-562 cells and TPO-

induced differentiation of HSC. Thapsigargin blocks SERCA, inducing protein misfolding and

the UPR, and altering $Ca^{2+}$ homeostasis [54-56]. Since DTT had no impact on megakaryocytic

maturation, it is likely that dysregulation of $Ca^{2+}$ homeostasis underlies inhibition of maturation

by thapsigargin. This is consistent with the known roles of intracellular $Ca^{2+}$ in

megakaryopoiesis. Activation of phospholipase C generates inositol trisphosphate (IP3)

triggering release of $Ca^{2+}$ from the ER via the IP3 receptor. Subsequent store-operated calcium

entry (SOCE) induces expression of nuclear factor of activated T cells (NFAT), a transcriptional

regulator implicated in megakaryopoiesis [57-59]. Additionally, $Ca^{2+}$entry through a

membranous $Ca^{2+}$ ion channel supports megakaryocyte differentiation [60, 61]. $Ca^{2+}$-dependent

activation of $Ca^{2+}$/calmodulin-dependent protein kinase (CaMK) induces transcription of CREB

(c-AMP response element-binding protein) to activate the genes with CRE elements, including

megakaryocyte-lineage specific genes such as *FLI1*, *HOXC6*, *MXD3*, *PRDM16*, *FOXB1*, *TBX6*,

*HDAC11* and *NPAS1* [58, 59, 62]. Finally, changes in intracellular $Ca^{2+}$ homeostasis occur in

myeloproliferative neoplasms and may contribute to disease pathogenesis through ER stress [63-

66].

Megakaryocyte differentiation is a complex process that requires the activation of several

synergistic pathways. Our findings indicate that the IRE-1-mediated adaptive UPR, rather than

an apoptotic response, is involved in megakaryocyte differentiation, and provide further evidence

for the importance of calcium signaling in megakaryopoiesis.

**Statements and Declarations**

**Funding**: This work was supported by Leukaemia & Blood Cancer New Zealand (to ECL),
University of Otago School of Biomedical Sciences Dean's Bequest Fund (to ECL), and
Auckland Medical Research Foundation (to MK-Z). Author MF was supported by a University
of Otago Doctoral Scholarship. Authors MPH and DCS were supported by Cancer Society
Auckland/Northland.

**Competing interests:** The authors have no competing interests to declare.

**Author contributions:** ECL and MK-Z conceived the study. ECL, MK-Z and MF designed the
study. Experimental work was performed by MF. All authors contributed to data analysis. The
first draft of the manuscript was written by MF and all authors commented on previous versions
of the manuscript. All authors read and approved the final manuscript.

**Data availability:** Data and materials are included within the article or Supplementary
Information are available from the authors on request.

**Ethics approval:** The study was approved by the University of Otago Human Ethics Committee
(NZ) (H20/132).

**Consent to participate:** Informed consent was obtained from all individual participants included
in the study.

**Acknowledgements**: Not applicable

## References

1.  Reid, D.W. and C.V. Nicchitta, *Diversity and selectivity in mRNA translation on the endoplasmic reticulum.* Nat Rev Mol Cell Biol, 2015. **16**: 221-31. 10.1038/nrm3958
2.  Braakman, I. and D.N. Hebert, *Protein folding in the endoplasmic reticulum.* Cold Spring Harb Perspect Biol, 2013. **5**: a013201. 10.1101/cshperspect.a013201
3.  Fagone, P. and S. Jackowski, *Membrane phospholipid synthesis and endoplasmic reticulum function.* J Lipid Res, 2009. **50 Suppl**: S311-6. 10.1194/jlr.R800049-JLR200
4.  Clapham, D.E., *Calcium signaling.* Cell, 2007. **131**: 1047-58. 10.1016/j.cell.2007.11.028
5.  Feral, K., et al., *ER Stress and Unfolded Protein Response in Leukemia: Friend, Foe, or Both?* Biomolecules, 2021. **11**: 199. 10.3390/biom11020199
6.  Hetz, C., K. Zhang, and R.J. Kaufman, *Mechanisms, regulation and functions of the unfolded protein response.* Nat Rev Mol Cell Biol, 2020. **21**: 421-438. 10.1038/s41580-020-0250-z
7.  Baek, H.A., et al., *Involvement of endoplasmic reticulum stress in myofibroblastic differentiation of lung fibroblasts.* Am J Respir Cell Mol Biol, 2012. **46**: 731-9. 10.1165/rcmb.2011-0121OC
8.  Saito, A., et al., *Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2.* J Biol Chem, 2011. **286**: 4809-18. 10.1074/jbc.M110.152900
9.  Tanimura, A., et al., *Mitochondrial Activity and Unfolded Protein Response are Required for Neutrophil Differentiation.* Cell Physiol Biochem, 2018. **47**: 1936-1950. 10.1159/000491464
10. Ma, Y., et al., *Plasma cell differentiation initiates a limited ER stress response by specifically suppressing the PERK-dependent branch of the unfolded protein response.* Cell Stress Chaperones, 2010. **15**: 281-93. 10.1007/s12192-009-0142-9
11. Tsuchiya, M., et al., *The role of unfolded protein response in differentiation of mammary epithelial cells.* Biochem Biophys Res Commun, 2017. **484**: 903-908. 10.1016/j.bbrc.2017.02.042
12. Lopez, J.J., et al., *Crucial role for endoplasmic reticulum stress during megakaryocyte maturation.* Arterioscler Thromb Vasc Biol, 2013. **33**: 2750-8. 10.1161/ATVBAHA.113.302184
13. Morishima, N. and K. Nakanishi, *Proplatelet formation in megakaryocytes is associated with endoplasmic reticulum stress.* Genes Cells, 2016. **21**: 798-806. 10.1111/gtc.12384
14. Nam, A.S., et al., *Somatic mutations and cell identity linked by Genotyping of Transcriptomes.* Nature, 2019. **571**: 355-360. 10.1038/s41586-019-1367-0
15. El-Khoury, M., et al., *Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms.* Oncogene, 2020. 10.1038/s41388-020-1368-3
16. Fosselteder, J., et al., *Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.* Leukemia, 2023. **37**: 843-853. 10.1038/s41375-023-01848-6
17. Prins, D., et al., *The stem/progenitor landscape is reshaped in a mouse model of essential thrombocythemia and causes excess megakaryocyte production.* Sci Adv, 2020. **6**: eabd3139. 10.1126/sciadv.abd3139

18.  Jutzi, J.S., et al., *CALR-mutated cells are vulnerable to combined inhibition of the*
*proteasome and the endoplasmic reticulum stress response.* Leukemia, 2023. **37**: 359-369.
10.1038/s41375-022-01781-0
19.  Ogura, M., et al., *Establishment of a novel human megakaryoblastic leukemia cell line,*
*MEG-01, with positive Philadelphia chromosome.* Blood, 1985. **66**: 1384-92.
10.1182/blood.V66.6.1384.1384
20.  Tabilio, A., et al., *Myeloid and megakaryocytic properties of K-562 cell lines.* Cancer Res,
1983. **43**: 4569-74.
21.  Balduini, A., et al., *Proplatelet formation in heterozygous Bernard-Soulier syndrome type*
*Bolzano.* J Thromb Haemost, 2009. **7**: 478-84. 10.1111/j.1538-7836.2008.03255.x
22.  Ong, L., I.M. Morison, and E.C. Ledgerwood, *Megakaryocytes from CYCS mutation-*
*associated thrombocytopenia release platelets by both proplatelet-dependent and -*
*independent processes.* Br J Haematol, 2017. **176**: 268-279. 10.1111/bjh.14421
23.  Hay, B.A., et al., *Aminopyrrolidineamide inhibitors of site-1 protease.* Bioorg Med Chem
Lett, 2007. **17**: 4411-4. 10.1016/j.bmcl.2007.06.031
24.  Smith, A.L., et al., *Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors*
*of protein kinase R-like endoplasmic reticulum kinase (PERK).* J Med Chem, 2015. **58**:
1426-41. 10.1021/jm5017494
25.  Patterson, J.B. and D.G. Lonergan, *IRE-1alpha inhibitors*, in *PATENTSCOPE*, P.C. Treaty,
Editor. 2008: USA.
26.  Pfaffl, M.W., *A new mathematical model for relative quantification in real-time RT-PCR.*
Nucleic Acids Res, 2001. **29**: e45. 10.1093/nar/29.9.e45
27.  Vandesompele, J., et al., *Accurate normalization of real-time quantitative RT-PCR data by*
*geometric averaging of multiple internal control genes.* Genome Biol, 2002. **3**:
RESEARCH0034. 10.1186/gb-2002-3-7-research0034
28.  Kamal, T., et al., *N-methyl-d-aspartate receptor mediated calcium influx supports in vitro*
*differentiation of normal mouse megakaryocytes but proliferation of leukemic cell lines.*
Res Pract Thromb Haemost, 2018. **2**: 125-138. 10.1002/rth2.12068
29.  Herrera, R., et al., *A Role of the MEK/MAPK Pathway in PMA-induced Cell Cycle Arrest:*
*Modulation of Megakaryocytic Differentiation of K-562 Cells.* Exp Cell Res, 1998. **238**:
407-414.
30.  Adams, C.J., et al., *Structure and Molecular Mechanism of ER Stress Signaling by the*
*Unfolded Protein Response Signal Activator IRE1.* Front Mol Biosci, 2019. **6**: 11.
10.3389/fmolb.2019.00011
31.  Reimold, A.M., et al., *An essential role in liver development for transcription factor XBP-*
*1.* Genes Dev, 1999. **14**: 152-157.
32.  Reimold, A.M., et al., *Plasma cell differentiation requires the transcription factor XBP-1.*
Nature, 2001. **412**: 300-7. 10.1038/35085509
33.  Klampfl, T., et al., *Somatic mutations of calreticulin in myeloproliferative neoplasms.* N
Engl J Med, 2013. **369**: 2379-90. 10.1056/NEJMoa1311347
34.  Nangalia, J., et al., *Somatic CALR mutations in myeloproliferative neoplasms with*
*nonmutated JAK2.* N Engl J Med, 2013. **369**: 2391-2405. 10.1056/NEJMoa1312542
35.  Clarke, M.C.H., et al., *Compartmentalized megakaryocyte death generates functional*
*platelets committed to caspase-independent death.* The Journal of Cell Biology, 2003. **160**:
577-587. 10.1083/jcb.200210111
36.  De Botton, S., et al., *Platelet formation is the consequence of caspase activation within*
*megakaryocytes.* Blood, 2002. **100**: 1310-1317. 10.1182/blood-2002-03-0686

37.   Josefsson, E.C., W. Vainchenker, and C. James, *Regulation of Platelet Production and Life*
*Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases.* Int J Mol
Sci, 2020. **21**. 10.3390/ijms21207591

38.   Josefsson, E.C., et al., *Platelet production proceeds independently of the intrinsic and*
*extrinsic apoptosis pathways.* Nature communications, 2014. **5**: 3455.
10.1038/ncomms4455

39.   Mazzi, S., et al., *Megakaryocyte and polyploidization.* Exp Hematol, 2018. **57**: 1-13.
10.1016/j.exphem.2017.10.001

40.   Lee, A.H., et al., *XBP-1 is required for biogenesis of cellular secretory machinery of*
*exocrine glands.* EMBO J, 2005. **24**: 4368-80. 10.1038/sj.emboj.7600903

41.   Lee, K., et al., *IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6*
*cleavage merge to regulate XBP1 in signaling the unfolded protein response.* Genes Dev,
2002. **16**: 452-66. 10.1101/gad.964702

42.   Sidrauski, C. and P. Walter, *The transmembrane kinase Ire1p is a site-specific*
*endonuclease that initiates mRNA splicing in the unfolded protein response.* Cell, 1997. **90**:
1031-1039. Doi 10.1016/S0092-8674(00)80369-4

43.   Abdullah, A. and P. Ravanan, *The unknown face of IRE1α - Beyond ER stress.* Eur J Cell
Biol, 2018. **97**: 359-368. 10.1016/j.ejcb.2018.05.002

44.   Lee, A.H., N.N. Iwakoshi, and L.H. Glimcher, *XBP-1 regulates a subset of endoplasmic*
*reticulum resident chaperone genes in the unfolded protein response.* Mol Cell Biol, 2003.
**23**: 7448-59. 10.1128/MCB.23.21.7448-7459.2003

45.   Tohmonda, T., et al., *The IRE1α-XBP1 pathway is essential for osteoblast differentiation*
*through promoting transcription of Osterix.* EMBO Rep, 2011. **12**: 451-7.
10.1038/embor.2011.34

46.   Levi-Ferber, M., et al., *Neuronal regulated ire-1-dependent mRNA decay controls germline*
*differentiation in Caenorhabditis elegans.* Elife, 2021. **10**. 10.7554/eLife.65644

47.   He, S., et al., *IRE1α regulates skeletal muscle regeneration through Myostatin mRNA*
*decay.* J Clin Invest, 2021. **131**. 10.1172/JCI143737

48.   Huang, H.W., et al., *The requirement of IRE1 and XBP1 in resolving physiological stress*
*during Drosophila development.* J Cell Sci, 2017. **130**: 3040-3049. 10.1242/jcs.203612

49.   Carrasco, D.R., et al., *The differentiation and stress response factor XBP-1 drives multiple*
*myeloma pathogenesis.* Cancer Cell, 2007. **11**: 349-60. 10.1016/j.ccr.2007.02.015

50.   Iwakoshi, N.N., L.H. Lee Ah Fau - Glimcher, and L.H. Glimcher, *The X-box binding*
*protein-1 transcription factor is required for plasma cell differentiation and the unfolded*
*protein response.* Immunol Rev 2003. **194**: 29-38.

51.   Hu, C.C., et al., *XBP-1 regulates signal transduction, transcription factors and bone*
*marrow colonization in B cells.* EMBO J, 2009. **28**: 1624-36. 10.1038/emboj.2009.117

52.   Leung-Hagesteijn, C., et al., *Xbp1s-negative tumor B cells and pre-plasmablasts mediate*
*therapeutic proteasome inhibitor resistance in multiple myeloma.* Cancer Cell, 2013. **24**:
289-304. 10.1016/j.ccr.2013.08.009

53.   Bettigole, S.E., et al., *The transcription factor XBP1 is selectively required for eosinophil*
*differentiation.* Nat Immunol, 2015. **16**: 829-37. 10.1038/ni.3225

54.   Jaskulska, A., A.E. Janecka, and K. Gach-Janczak, *Thapsigargin-From Traditional*
*Medicine to Anticancer Drug.* Int J Mol Sci, 2020. **22**. 10.3390/ijms22010004

55.   Sehgal, P., et al., *Inhibition of the sarco/endoplasmic reticulum (ER) Ca(2+)-ATPase by*
*thapsigargin analogs induces cell death via ER Ca(2+) depletion and the unfolded protein*
*response.* J Biol Chem, 2017. **292**: 19656-19673. 10.1074/jbc.M117.796920

56. Carreras-Sureda, A., P. Pihan, and C. Hetz, *Calcium signaling at the endoplasmic*
*reticulum: fine-tuning stress responses.* Cell Calcium, 2018. **70**: 24-31.
10.1016/j.ceca.2017.08.004
57. Zaslavsky, A., et al., *The calcineurin-NFAT pathway negatively regulates*
*megakaryopoiesis.* Blood, 2013. **121**: 3205-15. 10.1182/blood-2012-04-421172
58. Zhu, F., et al., *Screening for genes that regulate the differentiation of human*
*megakaryocytic lineage cells.* Proc Natl Acad Sci U S A, 2018. **115**: E9308-E9316.
10.1073/pnas.1805434115
59. Hogan, P.G., et al., *Transcriptional regulation by calcium, calcineurin, and NFAT.* Genes
Dev, 2003. **17**: 2205-32. 10.1101/gad.1102703
60. Hearn, J.I., et al., *N-Methyl-D-Aspartate Receptor Hypofunction in Meg-01 Cells Reveals a*
*Role for Intracellular Calcium Homeostasis in Balancing Megakaryocytic-Erythroid*
*Differentiation.* Thromb Haemost, 2020. **120**: 671-686. 10.1055/s-0040-1708483
61. Hearn, J.I., et al., *Deletion of Grin1 in mouse megakaryocytes reveals NMDA receptor role*
*in platelet function and proplatelet formation.* Blood, 2022. **139**: 2673-2690.
10.1182/blood.2021014000
62. Zhang, X., et al., *Genome-wide analysis of cAMP-response element binding protein*
*occupancy, phosphorylation, and target gene activation in human tissues.* Proc Natl Acad
Sci U S A, 2005. **102**: 4459-64. 10.1073/pnas.0501076102
63. Pietra, D., et al., *Differential clinical effects of different mutation subtypes in CALR-mutant*
*myeloproliferative neoplasms.* Leukemia, 2016. **30**: 431-8. 10.1038/leu.2015.277
64. Di Buduo, C.A., et al., *Defective interaction of mutant calreticulin and SOCE in*
*megakaryocytes from patients with myeloproliferative neoplasms.* Blood, 2020. **135**: 133-
144. 10.1182/blood.2019001103
65. Mosale Seetharam, S., et al., *Enkurin: A novel marker for myeloproliferative neoplasms*
*from platelet, megakaryocyte, and whole blood specimens.* Blood Adv, 2023.
10.1182/bloodadvances.2022008939
66. Immanuel, T., et al., *Deregulated calcium signaling in blood cancer: Underlying*
*mechanisms and therapeutic potential.* Front Oncol, 2022. **12**: 1010506.
10.3389/fonc.2022.1010506